Abstract
Background
Interleukin 27 (IL27) is a cytokine that belongs to IL12 family and it is mainly produced by antigen presenting cells. IL27 binding to its receptor leads to activation of many intracellular signaling pathways that can exhibit a wide variety of immunomodulatory actions.
Aim of the work
The current study aimed to determine IL27 concentrations in the sera of SSc patients and to assess the relation between these concentrations and the various clinical, laboratory and radiological disease parameters.
Methods
We measured serum IL27 concentrations in 31 SSc patients and 20 controls. The patients were subjected to detailed history and clinical evaluation. In SSc patients, modified Rodnan skin score (MRSS) was used to assess the skin thickness and pulmonary involvement was assessed by high resolution computerized tomography (HRCT) and forced vital capacity (FVC) assessment.
Results
IL27 serum concentrations in diffuse (median, 302.8; 101.6-1034.4 ng/L) and limited (median, 385; 109-826.3 ng/L) subtypes of SSc showed a significant elevation (P < 0.001) compared to its concentrations in the controls (median, 104.2; 51-184.2 ng/L). SSc patients with elevated IL27 serum concentrations had significantly lower forced vital capacity (FVC) than those with normal IL27 serum concentrations (p=0.04). Also, serum level of sCD163 significantly correlated with MRSS (r=0.48, p=0.0064) and FVC (r=-0.6, p=0.0005).
Conclusion
Patients with systemic sclerosis have significantly increased serum IL27 concentrations that remarkably associated with significant cutaneous and pulmonary involvement signifying that it could be a beneficial biomarker that reflects disease severity and implies a possible pathogenic role in SSc.
Article PDF
Similar content being viewed by others
References
Nihtyanova SI, Ong VH, Denton CP. Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl 81):156–164.
Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015; 6:272.
Altorok N, Kahaleh B. Epigenetics and systemic sclerosis. Semin Immunopathol 2015; 37:453–462.
Asano Y. Systemic sclerosis. J Dermatol 2018; 45:128–138.
Raker V, Haub J, Stojanovic A, Cerwenka A, Schuppan D, Steinbrink K. Early inflammatory players in cutanous fibrosis. J Dermatol Sci 2017; 87:228–235.
Dowson C, Simpson N, Duffy L, O’Reilly S. Innate immunity in systemic sclerosis. Curr Rheumatol Rep 2017; 19:2.
Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol 2015; 33:417–443.
Wittmann M, Zeitvogel J, Wang D, Werfel T. IL-27 is expressed in chronic human eczematous skin lesions and stimulates human keratinocytes. J Allergy Clin Immunol 2009; 124:81–89.
Kimura D, Miyakoda M, Kimura K, Honma K, Hara H, Yoshida H, et al. Interleukin 27 producing CD4(+) T cells regulate protective immunity during malaria parasite infection. Immunity 2016; 44:672–682.
Meka RR, Venkatesha SH, Dudics S, Acharya B, Moudgil KD. IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev 2015; 14:1131–1141.
Wang J, Wang G, Sun B, Li H, Mu L, Wang Q, et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 2008; 30:222–229.
Shen H, Xia L, Xiao W, Lu J. Increased levels of interleukin-27 in patients with rheumatoid arthritis. Arthritis Rheum 2011; 63:860–861.
Duarte AL, Dantas AT, de Ataíde Mariz H, dos Santos FA, da Silva JC, da Rocha LF Jr, et al. Decreased serum interleukin 27 in Brazilian systemic lupus erythematosus patients. Mol Biol Rep 2013; 40:4889–4892.
Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Muroi E, et al. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 2011; 70:194–200.
Shibata S, Tada Y, Kanda N, Nashiro K, Kamata M, Karakawa M, et al. Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 2010; 130:1034–1039.
Iwasaki Y, Fujio K, Okamura T, Yamamoto K. Interleukin-27 in T cell immunity. Int J Mol Sci 2015; 16:2851–2863.
Huber M, Steinwald V, Guralnik A, Brüstle A, Kleemann P, Rosenplänter C, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 2008; 20:223–234.
Yoshimoto T, Okada K, Morishima N, Kamiya S, Owaki T,Asakawa M, et al. Induction of IgG2a class switching in B cells by IL-27. J Immunol 2004; 173:2479–2485.
Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65:2737–2747.
Le Roy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger JrTA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202–205.
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437–2444.
Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995; 22:1281–1285.
Sakkas LI, Chikanza IC, Platsoucas CD. Mechanismsofdisease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2:679–685.
Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005; 64:1233–1235.
Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004; 50:1721–1733.
Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26:587–595.
Aparicio-Siegmund S, Garbers C. The biology of interleukin-27 reveals unique pro- and anti-inflammatory functions in immunity. Cytokine Growth Factor Rev 2015; 26:579–586.
Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004; 172:2225–2231.
Kopiński P, Wandtke T, Dyczek A, Wędrowska E, Roży A, Senderek T, et al. Increased levels of interleukin 27 in patients with early clinical stages of non-small cell lung cancer. Pol Arch Intern Med 2018; 128:105–114.
Su Y, Yao H, Wang H, Xu F, Li D, Li D, et al. IL27 enhances innate immunity of human pulmonary fibroblasts and epithelial cells through upregulation of TLR4 expression. Am J Physiol Lung Cell Mol Physiol 2016; 310: L133–L141.
Dong Z, Lu X, Yang Y, Zhang T, Li Y, Chai Y, et al. IL-27 alleviates the bleomycin-induced pulmonary fibrosis by regulating the Th17 cell differentiation. BMC Pulm Med 2015; 15:13.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hassan, W.A., Hamaad, G.A., Sayed, E.A. et al. Clinical significance of interleukin 27 serum concentration in patients with systemic sclerosis: relation to clinical, laboratory and radiological parameters. Egypt Rheumatol Rehabil 46, 101–107 (2019). https://doi.org/10.4103/err.err_63_18
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/err.err_63_18